United Therapeutics Corporation
United Therapeutics Announces Record Q4 and Full-Year 2023 Revenues and Files Lawsuit Against FDA
Summary
United Therapeutics Corporation reported record financial results for the quarter and full year 2023, with revenues increasing by 20% to $2.33 billion. The company also announced a lawsuit against the FDA regarding a New Drug Application amendment by Liquidia Technologies, Inc. The financial highlights include net income growth, increased revenues from key products, and a decrease in share-based compensation expense. The company granted restricted stock units to six new employees and will host a webcast to discuss these results.
Profitelligence Alerts
Get alerts for UTHR
Be first to know when United Therapeutics Corporation files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company engaged in the development and commercialization of innovative pharmaceutical products. Primarily focusing on therapies to address unmet medical needs for chronic and life-threatening conditions, United Therapeutics is notable for its contributions in the field of pulmonary arterial hypertension (PAH). The company offers a portfolio of products that include both oral and inhaled treatments, such as Remodulin and Tyvaso, providing critical care solutions that significantly improve patients' quality of life. Additionally, they are investing in innovative technologies such as organ manufacturing and regenerative medicine, showcasing a commitment to future medical advances. Headquartered in Silver Spring, Maryland, United Therapeutics operates across various stages of drug research, from clinical trials to post-market analysis. As a key player in the biotechnology industry, the company holds an influential position, contributing to significant advancements in therapeutic solutions and reinforcing its role in the healthcare market by addressing complex medical challenges and patient needs effectively.
Official SEC Documents
Advertisement